---
document_datetime: 2025-11-23 08:04:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/glubrava.html
document_name: glubrava.html
version: success
processing_time: 0.1635439
conversion_datetime: 2025-12-26 20:34:50.946354
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Glubrava

[RSS](/en/individual-human-medicine.xml/66811)

##### Withdrawn

This medicine's authorisation has been withdrawn

pioglitazone / metformin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Glubrava](#news-on)
- [More information on Glubrava](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24 May 2022 the European Commission withdrew the marketing authorisation for Glubrava (pioglitazone / metformin hydrochloride) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Takeda Pharma A/S, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Glubrava was granted marketing authorisation in the EU on 11 December 2007 for treatment of type 2 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2012. It was then granted unlimited validity in 2017. The product had not been marketed in the EU since 2021.

Glubrava is identical to Competact, which is authorised in the EU to treat type 2 diabetes mellitus in adult patients.

The European Public Assessment Report (EPAR) for Glubrava is updated to indicate that the marketing authorisation is no longer valid.

Glubrava : EPAR - Summary for the public

English (EN) (666.22 KB - PDF)

**First published:** 16/04/2008

**Last updated:** 18/10/2022

[View](/en/documents/overview/glubrava-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-103)

български (BG) (764.1 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/bg/documents/overview/glubrava-epar-summary-public_bg.pdf)

español (ES) (666.13 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/es/documents/overview/glubrava-epar-summary-public_es.pdf)

čeština (CS) (744.55 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/cs/documents/overview/glubrava-epar-summary-public_cs.pdf)

dansk (DA) (77.65 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/da/documents/overview/glubrava-epar-summary-public_da.pdf)

Deutsch (DE) (667.39 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/de/documents/overview/glubrava-epar-summary-public_de.pdf)

eesti keel (ET) (662.66 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/et/documents/overview/glubrava-epar-summary-public_et.pdf)

ελληνικά (EL) (766.94 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/el/documents/overview/glubrava-epar-summary-public_el.pdf)

français (FR) (667.47 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/fr/documents/overview/glubrava-epar-summary-public_fr.pdf)

hrvatski (HR) (686.01 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/hr/documents/overview/glubrava-epar-summary-public_hr.pdf)

italiano (IT) (664.57 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/it/documents/overview/glubrava-epar-summary-public_it.pdf)

latviešu valoda (LV) (102.29 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/lv/documents/overview/glubrava-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (101.74 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/lt/documents/overview/glubrava-epar-summary-public_lt.pdf)

magyar (HU) (735.5 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/hu/documents/overview/glubrava-epar-summary-public_hu.pdf)

Malti (MT) (746.85 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/mt/documents/overview/glubrava-epar-summary-public_mt.pdf)

Nederlands (NL) (664.67 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/nl/documents/overview/glubrava-epar-summary-public_nl.pdf)

polski (PL) (741.61 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/pl/documents/overview/glubrava-epar-summary-public_pl.pdf)

português (PT) (665.47 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/pt/documents/overview/glubrava-epar-summary-public_pt.pdf)

română (RO) (691.56 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/ro/documents/overview/glubrava-epar-summary-public_ro.pdf)

slovenčina (SK) (741.99 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/sk/documents/overview/glubrava-epar-summary-public_sk.pdf)

slovenščina (SL) (733.39 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/sl/documents/overview/glubrava-epar-summary-public_sl.pdf)

Suomi (FI) (663.56 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/fi/documents/overview/glubrava-epar-summary-public_fi.pdf)

svenska (SV) (665.12 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/sv/documents/overview/glubrava-epar-summary-public_sv.pdf)

Glubrava : EPAR - Risk-management-plan summary

English (EN) (835.01 KB - PDF)

**First published:** 04/03/2021

**Last updated:** 18/10/2022

[View](/en/documents/rmp-summary/glubrava-epar-risk-management-plan-summary_en.pdf)

## Product information

Glubrava : EPAR - Product Information

English (EN) (1.11 MB - PDF)

**First published:** 05/10/2009

**Last updated:** 18/10/2022

[View](/en/documents/product-information/glubrava-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-682)

български (BG) (2 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/bg/documents/product-information/glubrava-epar-product-information_bg.pdf)

español (ES) (1.14 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/es/documents/product-information/glubrava-epar-product-information_es.pdf)

čeština (CS) (1.7 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/cs/documents/product-information/glubrava-epar-product-information_cs.pdf)

dansk (DA) (1.09 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/da/documents/product-information/glubrava-epar-product-information_da.pdf)

Deutsch (DE) (1.16 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/de/documents/product-information/glubrava-epar-product-information_de.pdf)

eesti keel (ET) (1.18 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/et/documents/product-information/glubrava-epar-product-information_et.pdf)

ελληνικά (EL) (2.06 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/el/documents/product-information/glubrava-epar-product-information_el.pdf)

français (FR) (1.16 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/fr/documents/product-information/glubrava-epar-product-information_fr.pdf)

hrvatski (HR) (1.13 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/hr/documents/product-information/glubrava-epar-product-information_hr.pdf)

íslenska (IS) (1.11 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/is/documents/product-information/glubrava-epar-product-information_is.pdf)

italiano (IT) (1.14 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/it/documents/product-information/glubrava-epar-product-information_it.pdf)

latviešu valoda (LV) (365.53 KB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/lv/documents/product-information/glubrava-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.1 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/lt/documents/product-information/glubrava-epar-product-information_lt.pdf)

magyar (HU) (1.66 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/hu/documents/product-information/glubrava-epar-product-information_hu.pdf)

Malti (MT) (1.92 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/mt/documents/product-information/glubrava-epar-product-information_mt.pdf)

Nederlands (NL) (1.13 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/nl/documents/product-information/glubrava-epar-product-information_nl.pdf)

norsk (NO) (1.12 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/no/documents/product-information/glubrava-epar-product-information_no.pdf)

polski (PL) (1.69 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/pl/documents/product-information/glubrava-epar-product-information_pl.pdf)

português (PT) (347.68 KB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/pt/documents/product-information/glubrava-epar-product-information_pt.pdf)

română (RO) (1.17 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/ro/documents/product-information/glubrava-epar-product-information_ro.pdf)

slovenčina (SK) (1.7 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/sk/documents/product-information/glubrava-epar-product-information_sk.pdf)

slovenščina (SL) (1.66 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/sl/documents/product-information/glubrava-epar-product-information_sl.pdf)

Suomi (FI) (1.12 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/fi/documents/product-information/glubrava-epar-product-information_fi.pdf)

svenska (SV) (360.2 KB - PDF)

**First published:**

05/10/2009

**Last updated:**

18/10/2022

[View](/sv/documents/product-information/glubrava-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1979/G 04/02/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Glubrava : EPAR - All Authorised presentations

English (EN) (595.48 KB - PDF)

**First published:** 16/04/2008

**Last updated:** 18/10/2022

[View](/en/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-991)

български (BG) (641.13 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/bg/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_bg.pdf)

español (ES) (589.5 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/es/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_es.pdf)

čeština (CS) (615.69 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/cs/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (586.66 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/da/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (586.63 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/de/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (586.96 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/et/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (645.98 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/el/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_el.pdf)

français (FR) (586.79 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/fr/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (616.5 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/hr/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.17 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/is/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_is.pdf)

italiano (IT) (21.4 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/it/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (47.04 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/lv/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (46.25 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/lt/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (615.31 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/hu/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (635.76 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/mt/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (590.27 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/nl/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (589.63 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/no/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_no.pdf)

polski (PL) (618.53 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/pl/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_pl.pdf)

português (PT) (589.52 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/pt/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_pt.pdf)

română (RO) (620.82 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/ro/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (615.81 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/sk/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (615.09 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/sl/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (586.56 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/fi/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (586.87 KB - PDF)

**First published:**

16/04/2008

**Last updated:**

18/10/2022

[View](/sv/documents/all-authorised-presentations/glubrava-epar-all-authorised-presentations_sv.pdf)

Glubrava : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (590.65 KB - PDF)

**First published:** 06/07/2012

**Last updated:** 18/10/2022

[View](/en/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (24)](#file-language-dropdown-854)

български (BG) (689.11 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/bg/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (596.08 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/es/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (651 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/cs/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (590.13 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/da/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (598.58 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/de/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (591.19 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/et/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (689.76 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/el/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (596.62 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/fr/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

hrvatski (HR) (647.9 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/hr/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_hr.pdf)

íslenska (IS) (592.3 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/is/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (602.75 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/it/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (664.69 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/lv/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (623.34 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/lt/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (644.21 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/hu/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (650.11 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/mt/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (595.15 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/nl/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (20.23 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/no/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (653.62 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/pl/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (590.41 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/pt/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (623.15 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/ro/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (647.08 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/sk/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (648.05 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/sl/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (590.2 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/fi/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (591.74 KB - PDF)

**First published:**

06/07/2012

**Last updated:**

18/10/2022

[View](/sv/documents/conditions-member-states/glubrava-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Glubrava Active substance

- metformin hydrochloride
- pioglitazone hydrochloride

International non-proprietary name (INN) or common name

- pioglitazone
- metformin

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BD05

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Glubrava is indicated as second line treatment of type-2-diabetes-mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.

After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

## Authorisation details

EMA product number EMEA/H/C/000893 Marketing authorisation holder

Takeda Pharma A/S

Delta Park 45

Marketing authorisation issued 11/12/2007 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Glubrava : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (986.66 KB - PDF)

**First published:** 05/10/2009

**Last updated:** 18/10/2022

[View](/en/documents/procedural-steps-after/glubrava-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Glubrava-H-C-PSUSA-00002417-201807 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/241766/2019

English (EN) (648.24 KB - PDF)

**First published:** 12/08/2019

**Last updated:** 18/10/2022

[View](/en/documents/scientific-conclusion/glubrava-h-c-psusa-00002417-201807-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Glubrava : EPAR - Scientific Conclusion

English (EN) (616.67 KB - PDF)

**First published:** 17/01/2017

**Last updated:** 18/10/2022

[View](/en/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_en.pdf)

[Other languages (24)](#file-language-dropdown-54)

български (BG) (744.69 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/bg/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_bg.pdf)

español (ES) (612.56 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/es/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_es.pdf)

čeština (CS) (699.88 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/cs/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_cs.pdf)

dansk (DA) (611.38 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/da/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (618.28 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/de/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (609.98 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/et/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (745.86 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/el/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_el.pdf)

français (FR) (619.37 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/fr/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (647.9 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/hr/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_hr.pdf)

íslenska (IS) (613.54 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/is/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_is.pdf)

italiano (IT) (610.65 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/it/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (700.65 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/lv/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (650.77 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/lt/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_lt.pdf)

magyar (HU) (680 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/hu/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_hu.pdf)

Malti (MT) (702.62 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/mt/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (612.89 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/nl/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_nl.pdf)

norsk (NO) (609.48 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/no/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_no.pdf)

polski (PL) (698.04 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/pl/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_pl.pdf)

português (PT) (612.52 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/pt/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_pt.pdf)

română (RO) (649.5 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/ro/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (685.97 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/sk/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (691.33 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/sl/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (611.52 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/fi/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_fi.pdf)

svenska (SV) (612.69 KB - PDF)

**First published:**

17/01/2017

**Last updated:**

18/10/2022

[View](/sv/documents/scientific-conclusion/glubrava-epar-scientific-conclusion_sv.pdf)

Glubrava-H-C-893-PSUV-0029 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/566874/2013

English (EN) (679.21 KB - PDF)

**First published:** 19/12/2013

**Last updated:** 18/10/2022

[View](/en/documents/scientific-conclusion/glubrava-h-c-893-psuv-0029-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Glubrava-H-C-893-A20-0015 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/CHMP/940059/2011

English (EN) (955.23 KB - PDF)

**First published:** 07/05/2012

**Last updated:** 18/10/2022

[View](/en/documents/variation-report/glubrava-h-c-893-a20-0015-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Glubrava-H-A31-1432 : EPAR - Public assessment report - Article 31

English (EN) (1.31 MB - PDF)

**First published:** 17/01/2017

**Last updated:** 18/10/2022

[View](/en/documents/assessment-report/glubrava-h-a31-1432-epar-public-assessment-report-article-31_en.pdf)

Glubrava : EPAR - Procedural steps taken before authorisation

English (EN) (591.9 KB - PDF)

**First published:** 16/04/2008

**Last updated:** 18/10/2022

[View](/en/documents/procedural-steps/glubrava-epar-procedural-steps-taken-authorisation_en.pdf)

Glubrava : EPAR - Scientific Discussion

English (EN) (607.98 KB - PDF)

**First published:** 16/04/2008

**Last updated:** 18/10/2022

[View](/en/documents/scientific-discussion/glubrava-epar-scientific-discussion_en.pdf)

#### News on Glubrava

[Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function](/en/news/use-metformin-treat-diabetes-now-expanded-patients-moderately-reduced-kidney-function) 14/10/2016

[European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer](/en/news/european-medicines-agency-clarifies-opinion-pioglitazone-risk-bladder-cancer) 21/10/2011

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer](/en/news/european-medicines-agency-recommends-new-contra-indications-warnings-pioglitazone-reduce-small-increased-risk-bladder-cancer) 21/07/2011

[European Medicines Agency updates on ongoing benefit-risk review of pioglitazone-containing medicines](/en/news/european-medicines-agency-updates-ongoing-benefit-risk-review-pioglitazone-containing-medicines) 23/06/2011

[Update on ongoing European review of pioglitazone-containing medicines](/en/news/update-ongoing-european-review-pioglitazone-containing-medicines) 09/06/2011

#### More information on Glubrava

- [Metformin and metformin-containing medicines - referral](/en/medicines/human/referrals/metformin-metformin-containing-medicines)

**This page was last updated on** 18/10/2022

## Share this page

[Back to top](#main-content)